Xencor Inc (FRA:XE9)

€ 23.4 0.4 (1.74%) Market Cap: 1.63 Bil Enterprise Value: 1.19 Bil PE Ratio: 0 PB Ratio: 2.35 GF Score: 59/100

Q4 2023 Xencor Inc Earnings Call Transcript
Feb 27, 2024

€23.4 (-2.50%)

Earnings
Xencor Inc at JPMorgan Healthcare Conference Transcript
Jan 10, 2024
Q3 2023 Xencor Inc Earnings Call Transcript
Nov 07, 2023

€16.8

Earnings
Q2 2023 Xencor Inc Earnings Call Transcript
Aug 03, 2023

€21 (-1.87%)

Earnings
Q1 2023 Xencor Inc Earnings Call Transcript
May 08, 2023

€24.2 (-3.97%)

Earnings
Xencor Inc at Barclays Global Healthcare Conference Transcript
Mar 14, 2023
Q4 2022 Xencor Inc Earnings Call Transcript
Feb 23, 2023

€32 (+1.27%)

Earnings
Xencor Inc at JPMorgan Healthcare Conference Transcript
Jan 11, 2023
Q3 2022 Xencor Inc Earnings Call Transcript
Nov 07, 2022

€26.8

Earnings
Q2 2022 Xencor Inc Earnings Call Transcript
Aug 03, 2022

€29.4 (+8.89%)

Earnings
Q1 2022 Xencor Inc Earnings Call Transcript
May 05, 2022

€24.2 (+3.42%)

Earnings
Q4 2021 Xencor Inc Earnings Call Transcript
Feb 23, 2022

€28.14 (+0.18%)

Earnings
Xencor Inc at Guggenheim Partners Healthcare Talks Oncology Days (Virtual) Transcript
Feb 09, 2022
Xencor Inc at Credit Suisse Healthcare Conference (Virtual) Transcript
Nov 09, 2021
Q3 2021 Xencor Inc Earnings Call Transcript
Nov 08, 2021

€35.27 (-1.62%)

Earnings
Xencor Inc to Discuss Global Collaboration and License Agreement With Janssen Call Transcript
Oct 04, 2021
Q2 2021 Xencor Inc Earnings Call Transcript
Aug 04, 2021

€26.08 (+1.44%)

Earnings
Q1 2021 Xencor Inc Earnings Call Transcript
May 05, 2021

€33.58 (-3.62%)

Earnings
Xencor Inc at Barclays Global Healthcare Conference (Virtual) Transcript
Mar 10, 2021
Xencor Inc at SVB Leerink Global Healthcare Conference (Virtual) Transcript
Feb 24, 2021
Q4 2020 Xencor Inc Earnings Call Transcript
Feb 23, 2021

€39 (-2.99%)

Earnings
Xencor Inc at Jefferies Virtual London Healthcare Conference Transcript
Nov 19, 2020
Q3 2020 Xencor Inc Earnings Call Transcript
Nov 05, 2020

€35 (+4.79%)

Earnings
Q2 2020 Xencor Inc Earnings Call Transcript
Aug 04, 2020

€26.2 (+0.77%)

Earnings
Q1 2020 Xencor Inc Earnings Call Transcript
May 07, 2020

€28.2 (+2.17%)

Earnings
Q4 2019 Xencor Inc Earnings Call Transcript
Feb 24, 2020

€30.2 (-8.48%)

Earnings
Xencor Inc At The American Society Of Hematology (ASH) Annual Meeting Transcript
Dec 10, 2019
Q3 2019 Xencor Inc Earnings Call Transcript
Nov 05, 2019

€29.4 (-4.55%)

Earnings
Q2 2019 Xencor Inc Earnings Call Transcript
Aug 06, 2019

€39.08 (-0.96%)

Earnings
Xencor Inc at Bank of America Merrill Lynch Health Care Conference Transcript
May 15, 2019
Q1 2019 Xencor Inc Earnings Call Transcript
May 09, 2019

€28.38 (-4.19%)

Earnings
Q4 2018 Xencor Inc Earnings Call Transcript
Feb 25, 2019

Earnings

Xencor Inc at Guggenheim Partners Healthcare Talks Oncology Days (Virtual) Transcript

Feb 09, 2022 / 07:00PM GMT

Release Date Price: €30.88 (+5.79%)

Transcript 10-K8-K

Charles Zhu

Guggenheim Securities, LLC - Analyst

Hello, everyone, and welcome back. I'm Charles Zhu. I'm one of the senior biotech analysts here at Guggenheim Securities. Our next fireside chat will be with Xencor, a clinical-stage antibody and targeted-cytokine platform with an extensive array of various programs. Joining us today is CEO, Bassil Dahiyat. Bassil, thank you very much for your time today. Before we hop into Q&A, could you perhaps give us a three-minute overview of your company platform and pipeline?

Bassil Dahiyat

Xencor, Inc. - President & CEO

Absolutely. Thanks. It's a pleasure to be here at the conference today. Xencor is a protein-engineering company. We engineer antibodies and cytokines, as well as other proteins, to optimize how they engage with the immune system and how they're distributed to the body. We create molecules that have long duration of action, that are highly stable, and that are highly active, and that we hope effective in the treatment of cancers as well as in autoimmune diseases, the two areas we operate. Our

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.